Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40

Matching-adjusted indirect comparison of guselkumab versus risankizumab in patients with moderate-to-severe plaque psoriasis: Change in baseline Psoriasis Area and Severity Index from week 4 to 40

Bibliographic Details
Main Authors:	Richard G. Langley, MD, Chiranjeev Sanyal, PhD, Aaron Situ, MSc, Sarah Alulis, MSc, Fareen Hassan, MSc, Steve Peterson, MPH, Rachel E. Teneralli, PhD, Jennifer Lee, MBA, Barkha P. Patel, PhD, Tim Disher, PhD
Format:	Article
Language:	English
Published:	Elsevier 2024-06-01
Series:	JAAD International
Subjects:	change from baseline guselkumab indirect treatment comparisons matching-adjusted indirect comparison risankizumab PASI
Online Access:	http://www.sciencedirect.com/science/article/pii/S2666328724000166

Similar Items

Impact of PASI response on work productivity and the effect of risankizumab on indirect costs using machine learning in patients with moderate-to-severe psoriasis
by: Mark Lebwohl, et al.
Published: (2022-05-01)

Guselkumab, tildrakizumab, and risankizumab in a real-world setting: drug survival and effectiveness in the treatment of psoriasis and psoriatic arthritis
by: Cathrine Dawn Büttner Elgaard, et al.
Published: (2023-12-01)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Psoriasis: A Review of the Real-World Evidence
by: Ruggiero A, et al.
Published: (2022-08-01)

Real-world effectiveness and safety of risankizumab in patients with plaque psoriasis in whom guselkumab failed recently: A multicenter retrospective study of switching within the interleukin-23 inhibitor class
by: Ahmed Bagit, BSc, et al.
Published: (2023-09-01)

Work/study productivity gain and associated indirect cost savings with guselkumab compared with adalimumab in moderate-to-severe psoriasis: results from the VOYAGE 1 study
by: N. Li, et al.
Published: (2022-01-01)

Brodalumab Versus Guselkumab in Patients with Moderate-to-Severe Psoriasis with an Inadequate Response to Ustekinumab: A Randomized, Multicenter, Double-Blind Phase 4 Trial (COBRA)
by: Kristian Reich, et al.
Published: (2024-02-01)

Matching-adjusted indirect comparison (MAIC) results confirmed by head-to-head trials: a case study in psoriasis
by: James Signorovitch, et al.
Published: (2023-12-01)

Use of Guselkumab for the Treatment of Moderate-to-Severe Plaque Psoriasis: A 1 Year Real-Life Study
by: Marco Galluzzo, et al.
Published: (2020-07-01)

Real-world practice indirect comparison between guselkumab, risankizumab, and tildrakizumab: results from an Italian 28-week retrospective study
by: Matteo Megna, et al.
Published: (2022-08-01)

Management of Plaque Psoriasis: A Review and Comparison of IL-23 Inhibitors
by: Nicole L. Bolick, et al.
Published: (2020-12-01)

Efficacy and safety of risankizumab for moderate-to-severe plaque psoriasis in clinical practice: A 16-week Canadian retrospective multicenter cohort study
by: Yuliya Lytvyn, PhD, et al.
Published: (2022-03-01)

Guselkumab, Risankizumab, and Tildrakizumab in the Management of Hidradenitis Suppurativa: A Review of Existing Trials and Real-Life Data
by: Martora F, et al.
Published: (2023-09-01)

Comparison of the Efficacy and Safety of Biologics (Secukinumab, Ustekinumab, and Guselkumab) for the Treatment of Moderate-to-Severe Psoriasis: Real-World Data from a Single Korean Center
by: Seung-Won Jung, et al.
Published: (2022-05-01)

Risankizumab in the treatment of psoriasis – literature review
by: Katarzyna Banaszczyk
Published: (2019-06-01)

Guselkumab for the treatment of severe plaque psoriasis in a schizophrenia patient: a case report
by: Nicoletta Bernardini, et al.
Published: (2022-07-01)

A Case of Erythrodermic Psoriasis Successfully Treated with Risankizumab
by: Megna M, et al.
Published: (2023-12-01)

Risankizumab: an anti-IL-23 antibody for the treatment of psoriasis
by: Haugh IM, et al.
Published: (2018-11-01)

Clinical Utility of Guselkumab in the Treatment of Moderate-to-Severe Plaque Psoriasis
by: Light JG, et al.
Published: (2021-01-01)

Rapidly and successful improvement of nail psoriasis with risankizumab
by: Diego Orsini, et al.
Published: (2023-10-01)

A Review of the Efficacy and Safety for Biologic Agents Targeting IL-23 in Treating Psoriasis With the Focus on Tildrakizumab
by: Feras M. Ghazawi, et al.
Published: (2021-08-01)

An economic evaluation of risankizumab versus other biologic treatments of moderate to severe plaque psoriasis in Japan
by: Hidehisa Saeki, et al.
Published: (2022-01-01)

Matching-Adjusted Indirect Comparison of the Long-Term Efficacy of Deucravacitinib Versus Adalimumab for Moderate to Severe Plaque Psoriasis
by: April W. Armstrong, et al.
Published: (2023-07-01)

Erythrodermic Psoriasis Managed with Risankizumab
by: Abdulmajeed Alajlan, et al.
Published: (2022-08-01)

Super-Responders in Moderate–Severe Psoriasis under Guselkumab Treatment: Myths, Realities and Future Perspectives
by: Ricardo Ruiz-Villaverde, et al.
Published: (2022-09-01)

Drug survival of guselkumab in patients with plaque psoriasis: A 2 year retrospective, multicenter study
by: Yuliya Lytvyn, PhD, et al.
Published: (2021-09-01)

A severe psoriasis flare after COVID-19 treated with risankizumab: complete skin clearance after 16 weeks
by: Luciano Ibba, et al.
Published: (2023-06-01)

Real-life Effectiveness and Safety of Risankizumab in Moderate-to-severe Plaque Psoriasis: A 40-week Multicentric Retrospective Study
by: Riccardo G. Borroni, et al.
Published: (2021-11-01)

Risankizumab for the Treatment of Moderate to Severe Psoriasis: Impact on Health-Related Quality of Life and Psychological Wellbeing
by: Gracia-Cazaña T, et al.
Published: (2023-01-01)

Spotlight on risankizumab and its potential in the treatment of plaque psoriasis: evidence to date
by: Machado Á, et al.
Published: (2018-11-01)

Efficacy and safety of treatment of moderate and severe psoriasis with the interleukin 23 inhibitor risankizumab
by: Andrey L. Bakulev, et al.
Published: (2022-09-01)

Tildrakizumab for the Treatment of Moderate-to-Severe Psoriasis: Results from 52 Weeks Real-Life Retrospective Study
by: Ruggiero A, et al.
Published: (2023-02-01)

Indirect comparisons of ixekizumab versus three interleukin-23 p19 inhibitors in patients with moderate-to-severe plaque psoriasis – efficacy findings up to week 12
by: Alice B. Gottlieb, et al.
Published: (2022-01-01)

A non-clinical comparative study of IL-23 antibodies in psoriasis
by: Li Zhou, et al.
Published: (2021-01-01)

Use of risankizumab in two HIV-positive patients with psoriasis
by: Khalad Maliyar, MD, BA, et al.
Published: (2023-03-01)

Comparison of psoriasis guidelines for use of IL-23 inhibitors in the United States and United Kingdom: a critical appraisal and comprehensive review
by: R. I. Ghamrawi, et al.
Published: (2022-04-01)

Seven cancer patients receiving Guselkumab for treatment of moderate-to-severe psoriasis
by: Luca Mastorino, et al.
Published: (2022-03-01)

Risankizumab for the Treatment of the Patients with Moderate to Severe Plaque Psoriasis During a 24-Week Period: Real-Life Experience
by: Gönülal M, et al.
Published: (2023-12-01)

Efficacy of guselkumab versus secukinumab in subpopulations of patients with moderate-to-severe plaque psoriasis: results from the ECLIPSE study
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

Efficacy, safety, usability, and acceptability of risankizumab 150 mg formulation administered by prefilled syringe or by an autoinjector for moderate to severe plaque psoriasis
by: Andrew Blauvelt, et al.
Published: (2022-05-01)

Cost per responder for risankizumab vs secukinumab in patients with moderate-to-severe plaque psoriasis in Italy
by: Paolo Gisondi, et al.
Published: (2021-09-01)